Anti-Obesity Drugs Market is expected to reach US$ 43.7 billion by 2030 | Major Companies - Eli Lilly and Company, Bayer AG, Bristol-Myers Squibb, Currax Pharmaceuticals LLC, Merck & Co. Inc.

Market Size and Growth:

The Global Anti-Obesity Drugs Market size reached US$ 2.5 billion in 2022 and is expected to reach US$ 43.7 billion by 2030, growing with a CAGR of 45.5% during the forecast period 2024-2031.

The Anti-Obesity Drugs Market refers to the global industry focused on the development, production, and commercialization of pharmaceutical treatments designed to manage and reduce excess body weight. These drugs work through mechanisms such as appetite suppression, fat absorption inhibition, or metabolic enhancement. The market is driven by rising obesity prevalence, increasing awareness of weight-related health risks, and growing demand for effective medical therapies. It includes prescription medications, emerging biologics, and combination therapies used alongside lifestyle modifications.

Download Free Sample Report (Get Higher Priority for Corporate Email ID): https://datamintelligence.com/download-sample/anti-obesity-drugs-market?sz

Recent Key Developments of United States:

✅ March 2026: FDA approved setmelanotide (Imcivree) for acquired hypothalamic obesity, marking the first treatment for this rare condition and expanding the scope of obesity therapeutics beyond general weight loss.

✅ March 2026: FDA approved a higher-dose version (7.2 mg) of semaglutide (Wegovy) under a fast-track review program, demonstrating stronger weight-loss outcomes and accelerating innovation competition.

✅ January 2026: U.S. policy momentum increased with planned Medicare coverage expansion for obesity drugs and significant price reductions (as low as $245/month), improving patient access and market penetration.

✅ December 2025: Launch of the first oral GLP-1 weight-loss drug (Wegovy pill) in the U.S., improving accessibility and affordability compared to injectables and intensifying competition among major players.

Recent Key Developments of Japan:

✅ February 2026: Continued market growth driven by increasing obesity prevalence, lifestyle changes, and demand for appetite suppressants and combination drugs, with Japan emerging as a steadily expanding Asia-Pacific market.

✅ January 2026: Expansion of next-generation anti-obesity drug pipelines (oral GLP-1s and combination therapies) expected to impact Japan, where demand for convenient, non-injectable treatments is rising.

✅ December 2025: Global regulatory momentum (including WHO obesity guidelines recommending GLP-1 use) began influencing Japan's clinical and regulatory outlook toward structured obesity treatment approaches.

✅ November 2025: Rising adoption of GLP-1-based therapies and increasing recognition of obesity as a chronic disease globally influenced Japan's market growth trajectory and treatment frameworks.

List of the Key Players in the Anti-Obesity Drugs Market:

Eli Lilly and Company
Bayer AG
Bristol-Myers Squibb
Currax Pharmaceuticals LLC
F. Hoffmann-La Roche AG
GlaxoSmithKline PLC
Merck & Co. Inc.
Norgine BV
Novo Nordisk AS
Pfizer Inc.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/anti-obesity-drugs-market?sz

This Report Covers:

✔ Go-to-market Strategy.

✔ Neutral perspective on the market performance.

✔Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.

✔Customized regional/country reports as per request and country level analysis.

✔ Potential & niche segments and regions exhibiting promising growth covered.

✔ Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Segments Covered in the Anti-Obesity Drugs Market:

By Mechanism of Action: Peripherally Acting Drugs, Centrally Acting Drugs.

By Drug Type: Prescription Drugs, OTC Drugs.

By Route of Administration: Oral, Intravenous/Subcutaneous.

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=anti-obesity-drugs-market

Chapter Outline

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Anti-Obesity Drugs market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Anti-Obesity Drugs Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The Global Anti-Obesity Drugs market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Anti-Obesity Drugs Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the Anti-Obesity Drugs Market in 2025?
◆ What is the projected growth rate of the Anti-Obesity Drugs Market through 2033?
◆ Who are the key players in the Anti-Obesity Drugs Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.